New prostate cancer biomarkers provide hope to millions of men

UniSA researchers have identified three new biomarkers for prostate cancer to help identify and differentiate potentially aggressive cases of the disease which kills more than 300,000 men each year.

An international team of scientists led by UniSA Professor of Molecular Medicine Doug Brooks has made the breakthrough, which assists pathologists when visualising prostate cancer in patient tissue samples.

The new biomarkers, when used together, will assist clinicians in determining which patients require immediate, radical treatment compared to those who need close monitoring.
 

With more than one million men diagnosed with prostate cancer worldwide each year, the research breakthrough is significant.
 

The UniSA-based team has collaborated with the Australian company Envision Sciences on the technology to improve patient management and treatment outcomes.


“It is anticipated this will lead to long-term improvements in the way prostate cancer is diagnosed and graded,” Prof Brooks says.
 

“The biomarkers are remarkably sensitive and specific in accurately visualising the progress of the cancer and confirming its grade. This discovery has led to the commercial development of a test designed to determine how advanced and aggressive the cancer is and whether immediate treatment is needed.”
 

Envision Sciences, which funded the development and translation of the technology at UniSA, has signed a commercialisation agreement with the largest tissue diagnostic pathology company in the US, Quest Diagnostics, to take the technology into clinical practice.
 

Pending a successful outcome in the US, it is expected that clinical trials using the innovative technology will be undertaken in Australia.
 

Describing the breakthrough as “life saving,” UniSA Deputy Vice Chancellor Research and Enterprise Professor Marnie Hughes-Warrington AO says the partnership between UniSA and Envision Sciences is an exciting development in cancer research.
 

“This technology represents a shift in the way clinicians can grade and predict the aggressiveness of prostate cancer. We look forward to seeing the difference it makes in coming years.”